Salta alla navigazione principale
Salta alla ricerca
Salta al contenuto principale
Ordina per
Keyphrases
Renal Tubular Epithelial Cells
100%
Human Kidney
100%
Plasma-induced
100%
High-volume Hemofiltration
100%
Hemofiltration
90%
Endothelial Cells
36%
CD40 Ligand (CD40L)
27%
Fas Ligand
27%
Cell Injury
18%
Plasma Parameters
18%
Leukocyte Adhesion
18%
Von Willebrand Factor
18%
Septic Acute Kidney Injury
18%
Apoptosis
9%
No Significant Difference
9%
Protective Effect
9%
High Dose
9%
Altered Expression
9%
Adsorption
9%
Biological Effects
9%
Soluble Factors
9%
Plasma Concentration
9%
Detrimental Effects
9%
Randomized Clinical Trial
9%
Inflammatory Cytokines
9%
Inflammatory Mediators
9%
Albumin
9%
Functional Alterations
9%
Trial Registration
9%
Organ Dysfunction
9%
Antiangiogenic Activity
9%
Apoptotic Effect
9%
Septic Patients
9%
In Vitro Data
9%
Adhesion Receptors
9%
Caspase Activation
9%
Induced Endothelial Cells
9%
Tight Junction Proteins
9%
Megalin
9%
Epithelial Cell Injury
9%
Microvascular Injury
9%
Epithelial Cell Damage
9%
Adsorptive Membrane
9%
Harmful Practices
9%
Endothelial-derived Microparticles
9%
Activation Loss
9%
Endothelial Microparticles
9%
Cytokine Adsorption
9%
Cytokine Clearance
9%
Convective Therapies
9%
Pharmacology, Toxicology and Pharmaceutical Science
Tumor Necrosis Factor
100%
Cytokine
100%
Fas Ligand
100%
CD40 Ligand
100%
Microparticle
66%
Acute Kidney Failure
66%
Von Willebrand Factor
66%
Sepsis
66%
Receptor
33%
Randomized Clinical Trial
33%
Caspase
33%
Antiangiogenic
33%
Megalin
33%
Albumin
33%
Immunology and Microbiology
Blood Plasma
100%
Cell Damage
36%
Tumor Necrosis Factor
27%
Blood Level
27%
CD40 Ligand
27%
Fas Ligand
27%
Cytokine
18%
Upregulation
18%
Mediator
18%
Leukocyte Adherence
18%
Drug Megadose
9%
Experimental Model
9%
Antiangiogenic Activity
9%
Caspase
9%
Inflammatory Cytokine
9%
Tight Junction
9%
Programmed Cell Death
9%
Biological Activity
9%
Albumin
9%
Endothelial Microparticle
9%